Status: Not yet recruiting
A Phase I Clinical Study on the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Characteristics of GLR1075 Injection in Healthy Trial Participants and Cirrhotic Trial Participants With Ascites and Hypoalbuminemia
This trial is conducted in China. This study plans to include 3 parts,Part A, a single ascending dose (SAD) study in healthy trial participants; Part B, a multiple dose (MD) study in healthy trial participants; and Part C, a multiple ascending dose (MAD) study in cirrhotic trial participants with ascites and hypoproteinemia. All parts are intended to evaluate the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of GLR1075.
Participants needed: 106
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Gan & Lee Pharmaceuticals.Updated: Oct 1, 2026Locations: 1
Eligibility criteria
Signed informed consent form (ICF) prior to the trial, with a full understanding... [+16]
Individuals with an allergic constitution, or a history of allergic diseases suc... [+29]